Mobile

A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg, compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose in...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004993-26

A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg, compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose in patients with essential hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. Demonstrate the efficacy of aliskiren 300 mg following a missed dose by testing the hypothesis of superior mean 24 hour ambulatory diastolic blood pressure (MADBP) change from baseline compared to irbesartan 300 mg, 2. Demonstrate the efficacy of aliskiren 300 mg following a missed dose by testing the hypothesis of superior mean 24 hour ambulatory diastolic blood pressure (MADBP) change from baseline compared to ramipril 10 mg.

Critère d'inclusion

  • Hypertension

Liens